Generic Name:

Poractant alfa

Trade Name:

Curosurf

Action:

Exogenous pulmonary surfactant replacement for surfactant deficient neonates with respiratory distress syndrome

Indications:

Respiratory Distress Syndrome

Meconium Aspiration Syndrome

Administration Guidelines:

Usual Dosage Range and Route:

** FOR INTRATRACHEAL ADMINISTRATION ONLY **

First dose: 2.5 mL/kg

Subsequent doses: 1.25 mL/kg each at 12 hr intervals

•  Up to 2 repeat doses

Maximum total amount Curosurf : 5 mL/kg

Refer to Department of Respiratory Care Standard Operating Procedures for Administration Technique and Guidelines

Precautions and

Side Effects:

Transient Effects associated with instillation:

- Bradycardia

- Hypotension

- Endotracheal tube blockage

- Oxygen Desaturation

These events require stopping administration and taking appropriate measures to alleviate condition. Once stable, dosing may proceed with appropriate monitoring.

Special Considerations

Before use, the vial should be slowly warmed to room temperature and gently turned upside down, in order to obtain a uniform suspension. ** DO NOT SHAKE **

Correction of acidosis, hypotension, anemia, hypoglycemia and hypothermia is recommended before administration of Curosurf Ò

Marked improvements in oxygenation may occur within minutes of administration, therefore changes in lung compliance should be CLOSELY monitored and ventilator support adjusted as indicated.

Continuous heart rate and transcutaneous O 2 saturation should be monitored during administration; frequent ABG sampling is necessary to prevent postdosing hyperoxia and hypocarbia

Storage and Stability

Store in a refrigerator at 2 ° to 8 ° C (36 ° to 46 ° F)

Vials are SINGLE USE and should be discarded after initial entry

UNOPENED vials that have been warmed to room temperature CAN be returned to refrigerated storage within 24 hours. Vials can ONLY be warmed to room temperature and returned to refrigerator ONCE.